Compare HUBB & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBB | ZBH |
|---|---|---|
| Founded | 1888 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 19.5B |
| IPO Year | 2004 | 2001 |
| Metric | HUBB | ZBH |
|---|---|---|
| Price | $506.68 | $82.23 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 21 |
| Target Price | ★ $517.88 | $101.00 |
| AVG Volume (30 Days) | 485.6K | ★ 2.4M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | 1.04% | ★ 1.20% |
| EPS Growth | ★ 15.10 | N/A |
| EPS | ★ 16.54 | 3.55 |
| Revenue | $5,844,600,000.00 | ★ $8,231,500,000.00 |
| Revenue This Year | $10.41 | $4.96 |
| Revenue Next Year | $5.49 | $3.76 |
| P/E Ratio | $30.78 | ★ $23.12 |
| Revenue Growth | 3.84 | ★ 7.20 |
| 52 Week Low | $346.07 | $79.83 |
| 52 Week High | $565.50 | $108.29 |
| Indicator | HUBB | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 31.69 |
| Support Level | $461.20 | N/A |
| Resistance Level | $512.59 | $96.94 |
| Average True Range (ATR) | 15.54 | 2.82 |
| MACD | -2.86 | -1.44 |
| Stochastic Oscillator | 12.64 | 13.69 |
Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, in electrical substations, and in commercial and industrial buildings. The company's primary operations are in the United States, where around 90% of revenue is derived.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.